APA Alıntı

Xie, F., Feng, S., Sun, L., & Mao, Y. (2018). The first-line treatment for unresectable hepatocellular carcinoma patients: Lenvatinib versus sorafenib, or beyond? Hepatobiliary Surg Nutr.

Chicago Stili Alıntı

Xie, Feihu, Shi Feng, Lejia Sun, ve Yilei Mao. "The First-line Treatment for Unresectable Hepatocellular Carcinoma Patients: Lenvatinib Versus Sorafenib, or Beyond?" Hepatobiliary Surg Nutr 2018.

MLA Alıntı

Xie, Feihu, Shi Feng, Lejia Sun, ve Yilei Mao. "The First-line Treatment for Unresectable Hepatocellular Carcinoma Patients: Lenvatinib Versus Sorafenib, or Beyond?" Hepatobiliary Surg Nutr 2018.